Arbutus Biopharma (ABUS) vs Apnimed (APMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apnimed is the larger company by market cap ($669.8 million vs $616.2 million), about 1.1 times the size. On valuation, Apnimed trades at a lower trailing P/E (1.2x vs 3.6x for Arbutus Biopharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | APMD |
|---|---|---|
| Share price | $4.02 | $16.09 |
| Market cap | $616.24M | $669.84M |
| 1-day change | -1.23% | -6.70% |
| YTD return | -16.42% | — |
| 1-year return | -6.73% | — |
| 5-year return | +28.43% | — |
| P/E ratio (TTM) | 3.59 | 1.21 |
| EPS (TTM) | $1.12 | $13.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | — |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | — |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $35.29 |
| 52-week low | $3.50 | $13.88 |
| Distance from 52-week high | -26.24% | -54.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +32.34% | +210.75% |
| Average volume | 4.98M | 458.58K |
| Shares outstanding | 153.29M | 41.63M |
| Employees | 19 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Arbutus Biopharma trades at a higher earnings multiple (3.6x vs 1.2x trailing P/E).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
ABUS vs APMD FAQ
Which is bigger, Arbutus Biopharma or Apnimed?
Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $616.24M for Arbutus Biopharma (ABUS).
Which has the lower P/E ratio, ABUS or APMD?
APMD has the lower trailing P/E at 1.2, versus 3.6 for ABUS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and Apnimed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.